One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams

Protein Science

Volumn 25, Issue 4, 2016, Pages 787-803

  King, Dustin T ^a   Sobhanifar, Solmaz ^a   Strynadka, Natalie C J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

multidrug resistant bacteria; penicillin binding protein; resistance; lactam; lactamase

Indexed keywords

3 [[2 (2 AMINO 4 THIAZOLYL) 2 [[(1,4 DIHYDRO 1,5 DIHYDROXY 4 OXO 2 PYRIDINYL)METHOXY]IMINO]ACETYL]AMINO] 4 METHYL 2 OXO 1 AZETIDINESULFONIC ACID; AMPICILLIN; ASPERGILLOMARASMINE A; AVIBACTAM PLUS CEFTAROLINE; BAL 29880; BAL 90072; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFOXITIN; CEFTAROLINE; CEFTOBIPROLE; CEFTOLOZANE PLUS TAZOBACTAM; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CILASTATIN PLUS IMIPENEM PLUS RELEBACTAM; MERPENEM PLUS VABORBACTAM; ML 302F; NITROCEFIN; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PHENYLARGININE BETA NAPHTHYLAMIDE; PORIN; SIDEROPHORE; UNCLASSIFIED DRUG; VABORBACTAM; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CRYSTAL STRUCTURE; ENZYME INHIBITION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DRUG EFFECTS; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84960157138     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2889     Document Type: Review

References (138)

1. Lewis K, (2013) Platforms for antibiotic discovery. Nat Rev Drug Discov 12: 371-387.
2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J, (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1-12.
3. Davies J, Davies D, (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417-433.
4. Abraham EP, Chain E, (1988) An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis 10: 677-678.
5. Bush K, Fisher JF, (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu Rev Microbiol 65: 455-478.
6. Bush K, (2010) Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr Opin Microbiol 13: 558-564.
7. Baroud M, Dandache I, Araj GF, Wakim R, Kanj S, Kanafani Z, Khairallah M, Sabra A, Shehab M, Dbaibo G, Matar GM, (2013) Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases. Int J Antimicrob Agents 41: 75-79.
8. Rawat D, Nair D, (2010) Extended-spectrum β-lactamases in Gram negative bacteria. J Glob Infect Dis 2: 263-274.
9. Cole ST, (2014) Who will develop new antibacterial agents? Philos Trans R Soc London B Biol Sci 369: 20130430.
10. Tomanicek SJ, Standaert RF, Weiss KL, Ostermann A, Schrader TE, Ng JD, Coates L, (2013) Neutron and X-ray crystal structures of a perdeuterated enzyme inhibitor complex reveal the catalytic proton network of the Toho-1 β-lactamase for the acylation reaction. J Biol Chem 288: 4715-4722.
11. King DT, Strynadka NC, (2013) Targeting metallo-β-lactamase enzymes in antibiotic resistance. Future Med Chem 5: 1243-1263.
12. Bush K, (2013) The ABCD's of β-lactamase nomenclature. J Infect Chemother 19: 549-559.
13. Delmas J, Chen Y, Prati F, Robin F, Shoichet BK, Bonnet R, (2008) Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. J Mol Biol 375: 192-201.
14. Strynadka NC, Adachi H, Jensen SE, Johns K, Sielecki A, Betzel C, Sutoh K, James MN, (1992) Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution. Nature 359: 700-705.
15. Golemi D, Maveyraud L, Vakulenko S, Samama JP, Mobashery S, (2001) Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. Proc Natl Acad Sci USA 98: 14280-14285.
16. Chen Y, McReynolds A, Shoichet BK, (2009) Re-examining the role of Lys67 in class C beta-lactamase catalysis. Protein Sci 18: 662-669.
17. Papp-Wallace KM, Bethel CR, Gootz TD, Shang W, Stroh J, Lau W, McLeod D, Price L, Marfat A, Distler A, Drawz SM, Chen H, Harry E, Nottingham M, Carey PR, Buynak JD, Bonomo RA, (2012) Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone. Biochem Pharmacol 83: 462-471.
18. Drawz SM, Papp-Wallace KM, Bonomo RA, (2014) New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58: 1835-1846.
19. Bebrone C, Lassaux P, Vercheval L, Sohier JS, Jehaes A, Sauvage E, Galleni M, (2010) Current challenges in antimicrobial chemotherapy: focus on β-lactamase inhibition. Drugs 70: 651-679.
20. Shlaes DM, (2013) New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 1277: 105-114.
21. Livermore DM, Mushtaq S, (2013) Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 68: 1825-1831.
22. Coleman K, (2011) Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 14: 550-555.
23. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL, (2013) Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem 288: 27960-27971.
24. Lagacé-Wiens P, Walkty A, Karlowsky JA, (2014) Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9: 13-25.
25. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, Docquier JD, (2013) Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 57: 2496-2505.
26. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL, (2012) Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 109: 11663-11668.
27. King DT, King AM, Lal SM, Wright GD, Strynadka NCJ, (2015) Molecular mechanism of avibactam-mediated β-lactamase inhibition. ACS Infect Dis 1: 175-184.
28. Smoum R, Rubinstein A, Dembitsky VM, Srebnik M, (2012) Boron containing compounds as protease inhibitors. Chem Rev 112: 4156-4220.
29. Baker SJ, Tomsho JW, Benkovic SJ, (2011) Boron-containing inhibitors of synthetases. Chem Soc Rev 40: 4279-4285.
30. Eidam O, Romagnoli C, Caselli E, Babaoglu K, Pohlhaus DT, Karpiak J, Bonnet R, Shoichet BK, Prati F, (2010) Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J Med Chem 53: 7852-7863.
31. Strynadka NC, Martin R, Jensen SE, Gold M, Jones JB, (1996) Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase. Nat Struct Biol 3: 688-695.
32. Yang W, Gao X, Wang B, (2003) Boronic acid compounds as potential pharmaceutical agents. Med Res Rev 23: 346-368.
33. Livermore DM, Mushtaq S, Warner M, (2010) Activity of BAL30376 (monobactam BAL19764+BAL29880+clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother 65: 2382-2395.
34. Page MG, Dantier C, Desarbre E, (2010) In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother 54: 2291-2302.
35. Crandon JL, Nicolau DP, (2013) Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging Gram-negative organisms, including metallo-β-lactamase producers. Antimicrob Agents Chemother 57: 3299-3306.
36. King AM, Reid-Yu SA, Wang W, King DT, Gianfranco DP, Strynadka NC, Walsh TR, Coombes BK, Wright GD, (2014) Aspergillomarasmine A overcomes metallo-beta-lactamase antibiotic resistance. Nature510: 503-506.
37. Tan Q, Ogawa AM, Raghoobar SL, Wisniewski D, Colwell L, Park YW, Young K, Hermes JD, Dininno FP, Hammond ML, (2011) Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg Med Chem Lett 21: 4363-4365.
38. Brem J, van Berkel SS, Aik W, Rydzik AM, Avison MB, Pettinati I, Umland KD, Kawamura A, Spencer J, Claridge TD, McDonough MA, Schofield CJ, (2014) Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition. Nat Chem 6: 1084-1090.
39. Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA, (2010) Penicillin sulfone inhibitors of class D beta-lactamases. Antimicrob Agents Chemother 54: 1414-1424.
40. Lambert PA, (2005) Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev 57: 1471-1485.
41. Chambers HF, Deleo FR, (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7: 629-641.
42. Arias CA, Murray BE, (2012) The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10: 266-278.
43. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P, (2008) The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev 32: 234-258.
44. Typas A, Banzhaf M, Gross CA, Vollmer W, (2012) From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat Rev Microbiol 10: 123-136.
45. Zapun A, Contreras-Martel C, Vernet T, (2008) Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev 32: 361-385.
46. Klein E, Smith DL, Laxminarayan R, (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 13: 1840-1846.
47. Lim D, Strynadka NC, (2002) Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 9: 870-876.
48. Zhang HZ, Hackbarth CJ, Chansky KM, Chambers HF, (2001) A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. Science 291: 1962-1965.
49. Archer GL, Niemeyer DM, Thanassi JA, Pucci MJ, (1994) Dissemination among staphylococci of DNA sequences associated with methicillin resistance. Antimicrob Agents Chemother 38: 447-454.
50. Fuda C, Hesek D, Lee M, Morio K, Nowak T, Mobashery S, (2005) Activation for catalysis of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus by bacterial cell wall. J Am Chem Soc 127: 2056-2057.
51. De Lencastre H, Wu SW, Pinho MG, Ludovice AM, Filipe S, Gardete S, Sobral R, Gill S, Chung M, Tomasz A, (1999) Antibiotic resistance as a stress response: complete sequencing of a large number of chromosomal loci in Staphylococcus aureus strain COL that impact on the expression of resistance to methicillin. Microb Drug Resist 5: 163-175.
52. Brown S, Xia G, Luhachack LG, Campbell J, Meredith TC, Chen C, Winstel V, Gekeler C, Irazoqui JE, Peschel A, Walker S, (2012) Methicillin resistance in Staphylococcus aureus requires glycosylated wall teichoic acids. Proc Natl Acad Sci USA 109: 18909-18914.
53. Lu WP, Kincaid E, Sun Y, Bauer MD, (2001) Kinetics of beta-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in beta-lactam resistance. J Biol Chem 276: 31494-31501.
54. Lu WP, Sun Y, Bauer MD, Paule S, Koenigs PM, Kraft WG, (1999) Penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus: kinetic characterization of its interactions with beta-lactams using electrospray mass spectrometry. Biochemistry 38: 6537-6546.
55. Bush K, Heep M, Macielag MJ, Noel GJ, (2007) Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 16: 419-429.
56. Murthy B, Schmitt-Hoffmann A, (2008) Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 47: 21-33.
57. Queenan AM, Shang W, Kania M, Page MG, Bush K, (2007) Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother 51: 3089-3095.
58. Page MG, (2004) Cephalosporins in clinical development. Expert Opin Investig Drugs 13: 973-985.
59. Lovering AL, Gretes MC, Safadi SS, Danel F, de Castro L, Page MG, Strynadka NC, (2012) Structural insights into the anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of ceftobiprole. J Biol Chem 287: 32096-32102.
60. Mobley DL, Dill KA, (2009) Binding of small-molecule ligands to proteins: "what you see" is not always "what you get ". Structure 17: 489-498.
61. Graves-Woodward K, Pratt RF, (1998) Reaction of soluble penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus with beta-lactams and acyclic substrates: kinetics in homogeneous solution. Biochem J 332: 755-761.
62. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S, (2008) Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics. J Am Chem Soc 130: 9212-9213.
63. Otero LH, Rojas-Altuve A, Llarrull LI, Carrasco-Lõpez C, Kumarasiri M, Lastochkin E, Fishovitz J, Dawley M, Hesek D, Lee M, Johnson JW, Fisher JF, Chang M, Mobashery S, Hermoso JA, (2013) How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc Natl Acad Sci USA 110: 16808-16813.
64. Saravolatz LD, Stein GE, Johnson LB, (2011) Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 52: 1156-1163.
65. Moisan H, Pruneau M, Malouin F, (2010) Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 65: 713-716.
66. Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M, (2005) In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob Agents Chemother 49: 4185-4196.
67. O'Daniel PI, Peng Z, Pi H, Testero SA, Ding D, Spink E, Leemans E, Boudreau MA, Yamaguchi T, Schroeder VA, Wolter WR, Llarrull LI, Song W, Lastochkin E, Kumarasiri M, Antunes NT, Espahbodi M, Lichtenwalter K, Suckow MA, Vakulenko S, Mobashery S, Chang M, (2014) Discovery of a new class of non-β-lactam inhibitors of penicillin-binding proteins with Gram-positive antibacterial activity. J Am Chem Soc 136: 3664-3672.
68. Fox PM, Lampen RJ, Stumpf KS, Archer GL, Climo MW, (2006) Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics. Antimicrob Agents Chemother 50: 2951-2956.
69. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC, (2013) beta-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 58: 102-109.
70. Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR, Group T-I (2012) TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 56: 5476-5483.
71. Blais J, Lewis SR, Krause KM, Benton BM, (2011) Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic. Antimicrob Agents Chemother 56: 1584-1587.
72. Rice LB, Carias LL, Rudin S, Lakticová V, Wood A, Hutton-Thomas R, (2005) Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob Agents Chemother 49: 5007-5012.
73. Sauvage E, Kerff F, Fonzé E, Herman R, Schoot B, Marquette JP, Taburet Y, Prevost D, Dumas J, Leonard G, Stefanic P, Coyette J, Charlier P, (2002) The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin. Cell Mol Life Sci 59: 1223-1232.
74. Henry X, Amoroso A, Coyette J, Joris B, (2010) Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium. Antimicrob Agents Chemother 54: 953-955.
75. Cornick JE, Bentley SD, (2012) Streptococcus pneumoniae: the evolution of antimicrobial resistance to beta-lactams, fluoroquinolones and macrolides. Microbes Infect 14: 573-583.
76. Hakenbeck R, (1998) Mosaic genes and their role in penicillin-resistant Streptococcus pneumoniae. Electrophoresis 19: 597-601.
77. Chesnel L, Pernot L, Lemaire D, Champelovier D, Croizé J, Dideberg O, Vernet T, Zapun A, (2003) The structural modifications induced by the M339F substitution in PBP2x from Streptococcus pneumoniae further decreases the susceptibility to beta-lactams of resistant strains. J Biol Chem 278: 44448-44456.
78. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama S, Kitawaki J, Unemo M, (2011) Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55: 3538-3545.
79. Chantratita N, Rholl DA, Sim B, Wuthiekanun V, Limmathurotsakul D, Amornchai P, Thanwisai A, Chua HH, Ooi WF, Holden MT, Day NP, Tan P, Schweizer HP, Peacock SJ, (2011) Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc Natl Acad Sci U S A 108: 17165-17170.
80. Galdiero S, Falanga A, Cantisani M, Tarallo R, Della Pepa ME, D'Oriano V, Galdiero M, (2013) Microbe-host interactions: structure and role of Gram-negative bacterial porins. Curr Protein Pept Sci 13: 843-854.
81. Fernandez L, Hancock RE, (2012) Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 25: 661-681.
82. Harder KJ, Nikaido H, Matsuhashi M, (1981) Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin. Antimicrob Agents Chemother 20: 549-552.
83. Lou H, Chen M, Black SS, Bushell SR, Ceccarelli M, Mach T, Beis K, Low AS, Bamford VA, Booth IR, Bayley H, Naismith JH, (2011) Altered antibiotic transport in OmpC mutants isolated from a series of clinical strains of multi-drug resistant E. coli. PLoS One 6: e25825
84. Wolter DJ, Hanson ND, Lister PD, (2004) Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 236: 137-143.
85. Ochs MM, McCusker MP, Bains M, Hancock RE, (1999) Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 43: 1085-1090.
86. Huang H, Hancock RE, (1996) The role of specific surface loop regions in determining the function of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa. J Bacteriol 178: 3085-3090.
87. Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T, Jiang D, Gaultier C, Guerin Fo Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB, (2013) Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci USA 110: 20747-20752.
88. Raymond KN, Dertz EA, Kim SS, (2003) Enterobactin: an archetype for microbial iron transport. Proc Natl Acad Sci USA 100: 3584-3588.
89. Mollmann U, Heinisch L, Bauernfeind A, Kohler T, Ankel-Fuchs D, (2009) Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 22: 615-624.
90. Holden VI, Bachman MA, (2015) Diverging roles of bacterial siderophores during infection. Metallomics 7: 986-995.
91. Schalk IJ, Mislin GL, Brillet K, (2012) Structure, function and binding selectivity and stereoselectivity of siderophore-iron outer membrane transporters. Curr Top Membr 69: 37-66.
92. Noinaj N, Guillier M, Barnard TJ, Buchanan SK, (2010) TonB-dependent transporters: regulation, structure, and function. Annu Rev Microbiol 64: 43-60.
93. Pawelek PD, Croteau N, Ng-Thow-Hing C, Khursigara CM, Moiseeva N, Allaire M, Coulton JW, (2006) Structure of TonB in complex with FhuA, E. coli outer membrane receptor. Science 312: 1399-1402.
94. Chimento DP, Kadner RJ, Wiener MC, (2005) Comparative structural analysis of TonB-dependent outer membrane transporters: implications for the transport cycle. Proteins 59: 240-251.
95. Gause GF, (1955) Recent studies on albomycin, a new antibiotic. Br Med J 2: 1177-1179.
96. Bickel H, Mertens P, Prelog V, Seibl J, Walser A, (1965) Constitution of ferrimycin A1. Antimicrob Agents Chemother 5: 951-957.
97. Vértesy L, Aretz W, Fehlhaber H-W, Kogler H, (1995) Salmycin A-D, Antibiotika aus Streptomyces violaceus, DSM 8286, mit Siderophor-Aminoglycosid-Struktur. Helvetica Chim Acta 78: 46-60.
98. Page MG, (2013) Siderophore conjugates. Ann N Y Acad Sci 1277: 115-126.
99. Mislin GL, Schalk IJ, (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6: 408-420.
100. Butler MS, Blaskovich MA, Cooper MA, (2013) Antibiotics in the clinical pipeline in 2013. J Antibiot 66: 571-591.
101. Hofer B, Dantier C, Gebhardt K, Desarbre E, Schmitt-Hoffmann A, Page MG, (2013) Combined effects of the siderophore monosulfactam BAL30072 and carbapenems on multidrug-resistant Gram-negative bacilli. J Antimicrob Chemother 68: 1120-1129.
102. Higgins PG, Stefanik D, Page MG, Hackel M, Seifert H, (2012) In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. J Antimicrob Chemother 67: 1167-1169.
103. Mushtaq S, Warner M, Livermore D, (2010) Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother 65: 266-270.
104. Mima T, Kvitko BH, Rholl DA, Page MG, Desarbre E, Schweizer HP, (2011) In vitro activity of BAL30072 against Burkholderia pseudomallei. Int J Antimicrob Agents 38: 157-159.
105. Nikaido H, Pages JM, (2012) Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36: 340-363.
106. Martins A, Spengler G, Molnar J, Amaral L, (2012) Sequential responses of bacteria to noxious agents (antibiotics) leading to accumulation of mutations and permanent resistance. Biochem Pharmacol 1: 104.
107. Nikaido H, Takatsuka Y, (2009) Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta 1794: 769-781.
108. Li XZ, Livermore DM, Nikaido H, (1994) Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol, and norfloxacin. Antimicrob Agents Chemother 38: 1732-1741.
109. Su CC, Long F, Zimmermann MT, Rajashankar KR, Jernigan RL, Yu EW, (2011) Crystal structure of the CusBA heavy-metal efflux complex of Escherichia coli. Nature 470: 558-562.
110. Symmons MF, Bokma E, Koronakis E, Hughes C, Koronakis V, (2009) The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc Natl Acad Sci USA 106: 7173-7178.
111. Du D, Wang Z, James NR, Voss JE, Klimont E, Ohene-Agyei T, Venter H, Chiu W, Luisi BF, (2014) Structure of the AcrAB-TolC multidrug efflux pump. Nature 509: 512-515.
112. Hinchliffe P, Symmons MF, Hughes C, Koronakis V, (2013) Structure and operation of bacterial tripartite pumps. Annu Rev Microbiol 67: 221-242.
113. Du D, van Veen HW, Luisi BF, (2015) Assembly and operation of bacterial tripartite multidrug efflux pumps. Trends Microbiol 23: 311-319.
114. Murakami S, Nakashima R, Yamashita E, Yamaguchi A, (2002) Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419: 587-593.
115. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A, (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443: 173-179.
116. Pos KM, (2009) Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta 1794: 782-793.
117. Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K, Pos KM, (2006) Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313: 1295-1298.
118. Higgins MK, Bokma E, Koronakis E, Hughes C, Koronakis V, (2004) Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci USA 101: 9994-9999.
119. Mikolosko J, Bobyk K, Zgurskaya HI, Ghosh P, (2006) Conformational flexibility in the multidrug efflux system protein AcrA. Structure 14: 577-587.
120. Andersen C, Koronakis E, Bokma E, Eswaran J, Humphreys D, Hughes C, Koronakis V, (2002) Transition to the open state of the TolC periplasmic tunnel entrance. Proc Natl Acad Sci U S A 99: 11103-11108.
121. Bavro VN, Pietras Z, Furnham N, Perez-Cano L, Fernandez-Recio J, Pei XY, Misra R, Luisi B, (2008) Assembly and channel opening in a bacterial drug efflux machine. Mol Cell 30: 114-121.
122. Lewis K, (1994) Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem Sci 19: 119-123.
123. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ, (2007) Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 6: 56-65.
124. Li XZ, Ma D, Livermore DM, Nikaido H, (1994) Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother 38: 1742-1752.
125. Heritier C, Poirel L, Lambert T, Nordmann P, (2005) Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 49: 3198-3202.
126. Kaczmarek FS, Gootz TD, Dib-Hajj F, Shang W, Hallowell S, Cronan M, (2004) Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin. Antimicrob Agents Chemother 48: 1630-1639.
127. Pages JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, Noussair L, Nicolas-Chanoine MH, (2009) Efflux pump, the masked side of beta-lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One 4: e4817.
128. Sun J, Deng Z, Yan A, (2014) Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun 453: 254-267.
129. Venter H, Mowla R, Ohene-Agyei T, Ma S, (2015) RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 6: 377.
130. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ, (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 45: 105-116.
131. Hasdemir UO, Chevalier J, Nordmann P, Pages JM, (2004) Detection and prevalence of active drug efflux mechanism in various multidrug-resistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 42: 2701-2706.
132. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H, (2000) High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother 44: 3441-3443.
133. Watkins WJ, Landaverry Y, Leger R, Litman R, Renau TE, Williams N, Yen R, Zhang JZ, Chamberland S, Madsen D, Griffith D, Tembe V, Huie K, Dudley MN, (2003) The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors. Bioorg Med Chem Lett 13: 4241-4244.
134. Coban AY, Guney AK, Tanriverdi Cayci Y, Durupinar B, (2011) Effect of 1-(1-Naphtylmethyl)-piperazine, an efflux pump inhibitor, on antimicrobial drug susceptibilities of clinical Acinetobacter baumannii isolates. Curr Microbiol 62: 508-511.
135. Bohnert JA, Kern WV, (2005) Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 49: 849-852.
136. Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D, Kern WV, (2006) Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother 57: 344-348.
137. Kourtesi C, Ball AR, Huang YY, Jachak SM, Vera DM, Khondkar P, Gibbons S, Hamblin MR, Tegos GP, (2013) Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J 7: 34-52.
138. 2-lactam antibiotics against Escherichia coli by increasing antibiotic accumulation via inhibition of the multidrug efflux pump system AcrAB-TolC. J Antimicrob Chemother 66: 769-777.